Clinical trial NCT00635063: A Multicentre Study to Evaluate the Safety and Efficacy of AD 923 in Comparison to MSIR for the Treatment of CBP in Subjects
Official title: A Multicentre, Randomised, Double-Blind, Double-Dummy, Crossover Study to Evaluate the Safety and Efficacy of AD 923 (Fentanyl Sublingual) in Comparison to Morphine Sulphate Immediate Release (MSIR) for the Treatment of Breakthrough Pain in Subjects With Malignancies
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE3
Conditions: Cancer
Pain
Keywords: Cancer Breakthrough Pain
Lead sponsor: Sosei
Sponsor class: INDUSTRY
First posted: 2008-03-13
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: Purpose:

The purpose of this study is to compare the efficacy and safety of AD 923 to the most widely used current treatment (MSIR) in the management of target BTP in subjects with malignancies who are taking a stable dose of background opioids. The efficacy evaluation criteria have been designed to determine whether AD 923 provides superior analgesia compared with MSIR as measured by the primary endpoint.


Eligibility criteria: Main Inclusion Criteria:

* The subject is a male or female, at least 18 years of age.
* The subject has a malignancy, is receiving opioid therapy for his or her underlying persistent cancer pain, and is tolerant to the opioid therapy.
* The subject typically has 2 to 6 episodes of target BTP per day that require treatment.
* The subject has a life expectancy of \>3 months.
* The subject or his or her caregiver has easy, reliable access to a telephone.

Main Exclusion Criteria:

* The subject is a female who is pregnant or lactating.
* The subject has any respiratory or cardiac condition that, in the opinion of the investigator, may be clinically worsened by opioids.
* The subject has any allergy to the AD 923 product or excipients, namely: fentanyl, dehydrated alcohol, menthol, saccharin, and citrate buffer; or to the MSIR product excipients, namely: morphine sulphate, lactose (anhydrous), pregelatinized maize starch, povidone, purified water, magnesium stearate, talc, and tablet coatings.
* The subject has any neurological or psychiatric disease that, in the opinion of the investigator, would compromise data collection.
* The subject has uncontrolled or rapidly escalating pain.
* The subject has any significant laboratory test results that, in the opinion of the investigator, will compromise subject safety or the conduct of the study.
* The subject has plans to undergo chemotherapy, radiotherapy, or surgery during the treatment period. The exception is that subjects may continue chemotherapy over the study period, provided it is not expected to alter the pain state or response to pain medication.

Primary outcomes:
measure: To evaluate the efficacy of AD 923 in comparison to MSIR in the management of breakthrough pain in subjects with malignancies who are taking a stable dose of background opioids.
Secondary outcomes:
measure: To assess the safety and tolerability of AD 923 in the management of breakthrough pain in subjects with malignancies who are taking a stable dose of background opioids.
Other outcomes:
Locations:
city: Saffron Walden
country: United Kingdom
facility: Sosei R&D Ltd
state: Essex
Study officials:
affiliation: Royal Marsden NHS Foundation Trust
name: Andrew Davies, MBBS
role: PRINCIPAL_INVESTIGATOR
References: